Compo Mehltau-frei Kumulus WG

Hauptinformation

  • Handelsname:
  • Compo Mehltau-frei Kumulus WG
  • Verwenden für:
  • Pflanzen
  • Art der Medizin:
  • Agrochemisch

Dokumenten

  • Information für medizinisches Fachpersonal:
  • Das Informationsblatt für dieses Produkt ist derzeit nicht verfügbar, können Sie eine Anfrage an unseren Kundendienst zu senden und wir werden Sie benachrichtigen, sobald wir in der Lage, um es zu erhalten.


    Fordern Sie die Packungsbeilage für medizinisches Fachpersonal.

Lokalisierung

  • Erhältlich in:
  • Compo Mehltau-frei Kumulus WG
    Schweiz
  • Sprache:
  • Deutsch

Therapeutische Informationen

  • Therapiegruppe:
  • Akarizid Fungizid

Weitere Informationen

Status

  • Quelle:
  • UFAG - Ufficio federale dell'agricoltura. OFAG - Office fédéral de l'agriculture. BLW - Bundesamt für Landwirtschaft.
  • Zulassungsnummer:
  • D-2026
  • Letzte Änderung:
  • 06-09-2017

Packungsbeilage

Produkt:

Handelsbezeichnung: Compo Mehltau-frei Kumulus WG (Parallelimport)

Bewilligung beendet: Ausverkaufsfrist: 31.05.2018, Aufbrauchfrist: 31.05.2019

Produktekategorie

Ausl. Bewilligungsinhaber Eidg. Zulassungsnummer

Akarizid

Fungizid

Compo GMBH

D-2026

Packungsbeilagenummer Herkunftsland

Ausl. Zulassungsnummer

4571

Deutschland

2273-66

Stoff(e)

Gehalt

Formulierungscode

Wirkstoff: Schwefel

80 %

WG Wasserdispergierbares Granulat

Anwendungen

A Kultur

Schaderreger/Wirkung Dosierungshinweise

Auflagen

B Brombeere

Gallmilben

Konzentration: 1 %

Aufwandmenge: 10 kg/ha

Anwendung: Nach Austrieb, bei

Trieblänge 10-15 cm.

1, 2, 3

B Brombeere

Gallmilben

Konzentration: 2 %

Aufwandmenge: 20 kg/ha

Anwendung: Austriebsspritzung.

2, 3

B Erdbeere

Echter Mehltau der

Erdbeere

Konzentration: 0.2 - 0.4 %

Aufwandmenge: 2 - 4 kg/ha

3, 4, 5

O Kernobst

Echter Mehltau des

Apfels/der Birne

Teilwirkung:

Schorf des Kernobstes

Nebenwirkung:

Rostmilben

Konzentration: 0.3 - 0.5 %

Aufwandmenge: 4.8 - 8 kg/ha

Anwendung: Nach der Blüte.

3, 6, 7

A Kultur

Schaderreger/Wirkung Dosierungshinweise

Auflagen

O Kernobst

Echter Mehltau des

Apfels/der Birne

Teilwirkung:

Schorf des Kernobstes

Nebenwirkung:

Rostmilben

Konzentration: 0.5 - 0.75 %

Aufwandmenge: 8 - 12 kg/ha

Anwendung: Vor der Blüte.

3, 7

O Kernobst

Echter Mehltau des

Apfels/der Birne

Teilwirkung:

Schorf des Kernobstes

Nebenwirkung:

Rostmilben

Konzentration: 0.75 %

Aufwandmenge: 12 kg/ha

Anwendung: Beim Austrieb.

3, 7

O Pfirsich / Nektarine

Echter Mehltau des

Pfirsichs

Schorf des Pfirsichs

Konzentration: 0.3 - 0.5 %

Aufwandmenge: 4.8 - 8 kg/ha

Wartefrist: 3 Woche(n)

Anwendung: Nach der Blüte.

3, 7

O Steinobst

Schrotschuss

Nebenwirkung:

Rostmilben

Konzentration: 0.75 %

Aufwandmenge: 12 kg/ha

Anwendung: Vor der Blüte.

3, 7, 8

O Steinobst

Schrotschuss

Nebenwirkung:

Rostmilben

Konzentration: 0.3 - 0.5 %

Aufwandmenge: 4.8 - 8 kg/ha

Wartefrist: 3 Woche(n)

Anwendung: Nach der Blüte.

3, 7, 8

W Reben

Echter Mehltau der

Rebe

Konzentration: 0.1 - 0.4 %

Aufwandmenge: 1.6 - 6.4 kg/ha

Wartefrist: 3 Woche(n)

Anwendung: Vor- und

Nachblütebehandlungen bis spätestens

Mitte August.

3, 9, 10,

W Reben

Kräuselmilbe

Pockenmilbe der Reben

Konzentration: 2 %

Aufwandmenge: 16 kg/ha

Anwendung: Austriebsspritzung.

3, 12

Kürbisgewächse

(Cucurbitaceae)

Echter Mehltau der

Kürbisgewächse

Konzentration: 0.1 - 0.2 %

Aufwandmenge: 1 - 2 kg/ha

Wartefrist: 3 Tage

G Tomaten

Echter Mehltau der

Tomate

Konzentration: 0.1 - 0.2 %

Wartefrist: 3 Tage

Hopfen

Echter Mehltau des

Hopfens

Konzentration: 0.25 %

Wartefrist: 1 Woche(n)

Anwendung: Vorbeugend ab 1 m

Wuchshöhe.

3, 13

Z Bäume und Sträucher

(ausserhalb Forst)

Blumenkulturen und

Echte Mehltaupilze der

Zierpflanzen

Konzentration: 0.1 - 0.2 %

A Kultur

Schaderreger/Wirkung Dosierungshinweise

Auflagen

Grünpflanzen

Rosen

Z Kirschlorbeer

Schrotschuss

Konzentration: 0.1 - 0.2 %

Auflagen und Bemerkungen:

Bei stärkerem Befall zweite Behandlung.

Für Brombeeren bezieht sich die angegebene Aufwandmenge auf Stadium "Erste Blüten bis etwa

50% der Blüten offen" sowie eine Referenzbrühmenge von 1000 l/ha.

Ansetzen der Spritzbrühe: Schutzhandschuhe tragen.

Keine Behandlung von der Blüte bis zum Ende der Ernte.

Die angegebene Aufwandmenge bezieht sich auf Stadium "Vollblüte bis Beginn Rotfärbung der

Früchte", 4 Pflanzen pro m² sowie eine Referenzbrühmenge von 1000 l/ha.

Nachblütebehandlungen nur bei schwefelverträglichen Sorten.

Die angegebene Aufwandmenge bezieht sich auf ein Baumvolumen von 10'000 m³ pro ha.

Aprikosen sind schwefelempfindlich, keine Behandlungen.

Auch für die Luftapplikation.

10.Die angegebene Aufwandmenge bezieht sich auf Stadium BBCH 71-81 (J-M, Nachblüte) und

eine Referenzbrühemenge von 1600 l/ha (Berechnungsgrundlage) oder auf ein Laubwandvolumen

von 4500 m³ pro ha.

11.Höhere Aufwandmengen bei starkem Befallsdruck.

12.Die angegebene Aufwandmenge bezieht sich auf Stadium BBCH 15-51 (F) und eine

Referenzbrühmenge von 800 l/ha (Berechnungsgrundlage).

13.Maximal 15 Behandlungen im Abstand von ca. 7 Tagen pro Parzelle und Jahr.

Gefahrenkennzeichnungen:

Es gilt die Einstufung und Kennzeichnung der ausländischen Originaletikette.

Zusätzliche Schweizerische Gefahrenkennzeichnungen:

SP 1 Mittel und/oder dessen Behälter nicht in Gewässer gelangen lassen.

Im Zweifelsfall gelten einzig die Originaldokumente der Zulassung. Die Erwähnung eines Produktes,

Wirkstoffes oder einer Firma stellt keine Empfehlung dar und bedeutet nicht, dass sich das Produkt im

Verkauf befindet.

17-10-2018

Applicability of in silico tools for the prediction of dermal absorption for pesticides

Applicability of in silico tools for the prediction of dermal absorption for pesticides

Published on: Tue, 16 Oct 2018 00:00:00 +0200 Based on the “Human in vitro dermal absorption datasets” published as supporting information to the revised EFSA Guidance on Dermal Absorption, in silico models for prediction of absorption across the skin have been evaluated. For this evaluation, a systematic literature search and review was performed, identifying 288 publications describing mathematical models for prediction of dermal absorption. Eleven models potentially relevant to the regulatory assessm...

Europe - EFSA - European Food Safety Authority Publications

28-9-2018

Peer review of the pesticide risk assessment of the active substance ABE‐IT 56 (components of lysate of Saccharomyces cerevisiae strain DDSF623)

Peer review of the pesticide risk assessment of the active substance ABE‐IT 56 (components of lysate of Saccharomyces cerevisiae strain DDSF623)

Published on: Thu, 27 Sep 2018 00:00:00 +0200 The conclusions of EFSA following the peer review of the initial risk assessments carried out by the competent authority of the rapporteur Member State, France, for the pesticide active substance ABE‐IT 56 (components of lysate of Saccharomyces cerevisiae strain DDSF623) are reported. The context of the peer review was that required by Regulation (EC) No 1107/2009 of the European Parliament and of the Council. The conclusions were reached on the basis of the...

Europe - EFSA - European Food Safety Authority Publications

27-9-2018

Outcome of the consultation on confirmatory data used in risk assessment for the active substance  copper (I), copper (II) variants

Outcome of the consultation on confirmatory data used in risk assessment for the active substance copper (I), copper (II) variants

Published on: Wed, 26 Sep 2018 00:00:00 +0200 The European Food Safety Authority (EFSA) was asked by the European Commission to provide scientific assistance with respect to the risk assessment for an active substance in light of confirmatory data requested following the first approval in accordance with Article 6(1) of Directive 91/414/EEC and Article 6(f) of Regulation (EC) No 1107/2009. In this context EFSA's scientific views on the specific points raised during the commenting phase conducted with Me...

Europe - EFSA - European Food Safety Authority Publications

25-9-2018

Remarks from Anna Abram as prepared for delivery to the 2018 Intergovermental Meeting on Drug Compounding

Remarks from Anna Abram as prepared for delivery to the 2018 Intergovermental Meeting on Drug Compounding

Remarks by FDA’s Anna Abram to the 2018 Intergovermental Meeting on Drug Compounding

FDA - U.S. Food and Drug Administration

21-9-2018

FDA Animal Drug Safety Communication: FDA Reminds Veterinarians of the Differences Between Approved and Compounded Formulas of Transdermal Mirtazapine for the Management of Weight Loss in Cats

FDA Animal Drug Safety Communication: FDA Reminds Veterinarians of the Differences Between Approved and Compounded Formulas of Transdermal Mirtazapine for the Management of Weight Loss in Cats

CVM Update describing FDA Dear Veterinarian Letter about the differences between FDA-approved Mirataz (mirtazapine transdermal ointment), an animal drug with demonstrated safety and effectiveness to manage undesired weight loss in cats, and compounded formulations of transdermal mirtazapine.

FDA - U.S. Food and Drug Administration

19-9-2018

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

National dietary survey in 2012‐2016 on the general population aged 1‐79 years in the Netherlands

Published on: Tue, 18 Sep 2018 00:00:00 +0200 During the years 2012‐2016, the Dutch National Food Consumption survey was conducted in the Netherlands. For the survey, a random sample was drawn from consumer panels stratified by age and gender and maintained representative to the population with regard to region, address density and educational level. Complete results were obtained for 4,313 persons (response rate 65%); including toddlers, children, adolescents, adults and elderly. Pregnant or lactating ...

Europe - EFSA - European Food Safety Authority Publications

14-9-2018

Development of an automated multienzymatic biosensor for risk assessment of pesticide contamination in water and food

Development of an automated multienzymatic biosensor for risk assessment of pesticide contamination in water and food

Published on: Mon, 27 Aug 2018 00:00:00 +0200 The goal of this research is to better address the problems related to the widespread presence of pesticides in the environment. Despite the unquestionable utility of the pesticides against various pests in the agricultural field, most pesticides and the corresponding pesticide residues are toxic to the environment and hazardous to human health. The recent literature on organophosphate compounds emphasises a clear correlation between their use and the occurr...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Risk assessment of substances used in food supplements: the example of the botanical Gymnema sylvestre

Risk assessment of substances used in food supplements: the example of the botanical Gymnema sylvestre

Published on: Tue, 28 Aug 2018 00:00:00 +0200 Botanicals and preparations derived from these are among the substances frequently added to foods and food supplements, yet the safety of many botanicals has not been systematically assessed. In the context of the EU‐FORA fellowship programme, the fellow performed an assessment on the safety of the botanical Gymnema sylvestre, in accordance with EFSA's guidance on the assessment of safety of botanicals. Although preparations of G. sylvestre are marketed as f...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Risk assessment of white willow (Salix alba) in food

Risk assessment of white willow (Salix alba) in food

Published on: Tue, 28 Aug 2018 00:00:00 +0200 This Technical Report contains a description of the activities within the work programme of the EU‐FORA Fellowship on the risk assessment of white willow in food. The bark of different varieties of willow has had a long history of medical use as a means to reduce fever and as a painkiller. Willow bark is also used in weight loss and sports performance food supplements. The labelling of these products usually does not mention any restrictions to the length of...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Risk ranking of chemical and microbiological hazards in food

Risk ranking of chemical and microbiological hazards in food

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Risk ranking is a versatile tool used to prioritise activities performed by public health regulatory bodies. It also allows efficient communication between all stakeholders in the process of risk analysis. However, risk ranking methods are still not optimal. Because of the different approaches employed in the risk assessment of microbiological agents and chemicals, it is difficult to rank them together using the same metrics. In our work, we first discuss di...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Identification and evaluation of potentially mutagenic and carcinogenic food contaminants

Identification and evaluation of potentially mutagenic and carcinogenic food contaminants

Published on: Mon, 27 Aug 2018 00:00:00 +0200 Heat processing of food gives rise to a plethora of chemical compounds whose toxicological effects are largely unknown. Due to a general lack of experimental toxicological data, assessing the risks associated with the consumption of these substances remains a challenge. Computer models that allow for an in silico prediction of physicochemical and toxicological characteristics, may be able to fill current data gaps and facilitate the risk assessment of toxico...

Europe - EFSA - European Food Safety Authority Publications

11-9-2018

Pharm D Solutions, LLC Issues Voluntary Nationwide Recall of all Sterile Compounded Drugs Due to A Potential Lack of Sterility Assurance

Pharm D Solutions, LLC Issues Voluntary Nationwide Recall of all Sterile Compounded Drugs Due to A Potential Lack of Sterility Assurance

Pharm D Solutions, LLC is voluntarily recalling all sterile compounded drug products within expiry to the clinic, physician or consumer level. These drug products are being voluntarily recalled due to concerns that practices at the pharmacy have the potential to pose a risk of contamination to products that are intended to be sterile. These concerns arose following a routine inspection of the pharmacy by FDA.

FDA - U.S. Food and Drug Administration

7-9-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to help ensure the quality of and preserve access to compounded drugs by pursuing closer collaboration with states

Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to help ensure the quality of and preserve access to compounded drugs by pursuing closer collaboration with states

FDA announces revised draft memorandum of understanding between FDA and the states to help ensure the quality of and preserve access to compounded drugs

FDA - U.S. Food and Drug Administration

29-8-2018

Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms

Scientific Opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) effect models for regulatory risk assessment of pesticides for aquatic organisms

Published on: Thu, 23 Aug 2018 00:00:00 +0200 Following a request from EFSA, the Panel on Plant Protection Products and their Residues (PPR) developed an opinion on the state of the art of Toxicokinetic/Toxicodynamic (TKTD) models and their use in prospective environmental risk assessment (ERA) for pesticides and aquatic organisms. TKTD models are species‐ and compound‐specific and can be used to predict (sub)lethal effects of pesticides under untested (time‐variable) exposure conditions. Three differen...

Europe - EFSA - European Food Safety Authority Publications

20-8-2018

August 17, 2018: Unlicensed Pharmacy Technician Pleads Guilty to Working at New England Compounding Center

August 17, 2018: Unlicensed Pharmacy Technician Pleads Guilty to Working at New England Compounding Center

August 17, 2018: Unlicensed Pharmacy Technician Pleads Guilty to Working at New England Compounding Center

FDA - U.S. Food and Drug Administration

28-7-2018

Ranier’s Rx Laboratory Issues Voluntary Recall of All Sterile Compounded Products Within Expiry Due to Lack of Sterility Concerns

Ranier’s Rx Laboratory Issues Voluntary Recall of All Sterile Compounded Products Within Expiry Due to Lack of Sterility Concerns

Ranier’s Rx Laboratory is voluntarily recalling all sterile compounded drug products within expiry to the hospital or consumer level. These drug products are being voluntarily recalled due to concerns that practices at the pharmacy have the potential to pose a risk of contamination to products that are intended to be sterile. These concerns arose following a routine inspection of the pharmacy by FDA.

FDA - U.S. Food and Drug Administration

23-7-2018

FDA continues taking key actions on bulk drug substances used for compounding to advance the regulatory framework governing compounded drugs and to protect patients

FDA continues taking key actions on bulk drug substances used for compounding to advance the regulatory framework governing compounded drugs and to protect patients

FDA continues making progress on bulk drug substances for compounding

FDA - U.S. Food and Drug Administration

19-7-2018

Analgetika-Warnhinweis-Verordnung (AnalgetikaWarnHV) am 01.07.2018 in Kraft getreten

Analgetika-Warnhinweis-Verordnung (AnalgetikaWarnHV) am 01.07.2018 in Kraft getreten

Die Verordnung erfasst rezeptfreie Schmerzmittel, die zur Behandlung leichter bis mäßig starker Schmerzen oder von Fieber eingesetzt werden und beispielsweise die Wirkstoffe Paracetamol, Ibuprofen Diclofenac oder Acetylsalicylsäure (Aspirin) enthalten.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

4-7-2018

Dringende Sicherheitsinformation zu verschiedene Therapieliegen von FREI AG- Aktive Rehasysteme

Dringende Sicherheitsinformation zu verschiedene Therapieliegen von FREI AG- Aktive Rehasysteme

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

28-6-2018

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s continued efforts relating to compounded drugs for patients who cannot use an FDA-approved drug

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s continued efforts relating to compounded drugs for patients who cannot use an FDA-approved drug

Statement from FDA Commissioner Scott Gottlieb, M.D., on agency’s continued efforts relating to compounded drugs for patients who cannot use an FDA-approved drug

FDA - U.S. Food and Drug Administration

27-6-2018

Dringende Sicherheitsinformation zu Höhenverstellbarer Trainingstisch 43- 64 cm von FREI AG- Aktive Rehasysteme

Dringende Sicherheitsinformation zu Höhenverstellbarer Trainingstisch 43- 64 cm von FREI AG- Aktive Rehasysteme

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

25-6-2018

Statement by FDA Commissioner Scott Gottlieb, M.D., on the importance of conducting proper research to prove safe and effective medical uses for the active chemicals in marijuana and its components

Statement by FDA Commissioner Scott Gottlieb, M.D., on the importance of conducting proper research to prove safe and effective medical uses for the active chemicals in marijuana and its components

FDA Commissioner Scott Gottlieb, M.D., discusses the importance of conducting proper research to prove safe and effective medical uses for the active chemicals in marijuana and its components.

FDA - U.S. Food and Drug Administration

15-6-2018

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

Compounded Products Containing Triamcinolone-Moxifloxacin by Guardian Pharmacy Services (Dallas, Texas): Alert to Health Professionals - Adverse Events Reported After Receiving Eye Injections

At least 43 patient reported adverse event after receiving eye injections of Guardian’s Pharmacy Services compounded triamcinolone-moxifloxacin product during cataract surgery. The patients reportedly experienced various symptoms, including vision impairment, poor night vision, loss of color perception, and significant reductions in best-corrected visual acuity and visual fields. FDA identified multiple substances in Guardian’s product, including poloxamer 407 and poloxamer 407 degradants. FDA prepared i...

FDA - U.S. Food and Drug Administration

9-6-2018

Dringende Sicherheitsinformation zu verschiedene Therapieliegen, Arcus Motor von FREI AG- Aktive Rehasysteme

Dringende Sicherheitsinformation zu verschiedene Therapieliegen, Arcus Motor von FREI AG- Aktive Rehasysteme

Weitere Informationen sowie Details zum Produkt entnehmen Sie bitte der anliegenden Kundeninformation des Herstellers.

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

6-6-2018

CARDIOSAVE Hybrid Intra-aortic Balloon Pump by Maquet Datascope Corp.: Class I Recall - Due to Fluid Ingress that May Affect Device Operation and Interrupt or Delay Therapy

CARDIOSAVE Hybrid Intra-aortic Balloon Pump by Maquet Datascope Corp.: Class I Recall - Due to Fluid Ingress that May Affect Device Operation and Interrupt or Delay Therapy

Maquet Datascope Corp. is recalling the IABP due to a design issue that allows fluid (such as saline) to seep into the device. The fluid can cause corrosion of internal components such as the electronic circuit boards, and lead to device malfunction (e.g., sudden stops) which can cause a delay or interruption in therapy. Device failure may result in immediate and serious adverse health consequences, including death.

FDA - U.S. Food and Drug Administration

1-6-2018

Specialized Bicycle Components Canada, Inc. recalls Bicycles with Stout Crankarms

Specialized Bicycle Components Canada, Inc. recalls Bicycles with Stout Crankarms

The crankarm can disengage and cause the rider to lose control, posing fall and injury hazards.

Health Canada

31-5-2018

LFIT Anatomic CoCr V40 Femoral Heads

LFIT Anatomic CoCr V40 Femoral Heads

Hazard alert - potential for components to separate

Therapeutic Goods Administration - Australia

30-5-2018

Procleix West Nile Virus (WNV) Assay

Procleix West Nile Virus (WNV) Assay

Product approval information is indicated for the qualitative detection of West Nile Virus (WNV) RNA in plasma specimens from individual human donors, including volunteer donors of whole blood and blood components, and other living donors.

FDA - U.S. Food and Drug Administration

29-5-2018

Versorgung der Krankenhausapotheken - Besondere Situation der Krankenhausversorgung

Versorgung der Krankenhausapotheken - Besondere Situation der Krankenhausversorgung

Vortragsfolien von Prof. Dr. Martin Hug, Universitätsklinikum Freiburg, im Rahmen der Veranstaltung "BfArM im Dialog - Arzneimittelfälschungen und Umsetzung der Fälschungsschutzrichtlinie" vom 8. Mai 2018

Deutschland - BfArM - Bundesinstitut für Arzneimittel und Medizinprodukte

27-4-2018

ANSES assesses the efficacy and safety of alternatives to antibiotics in animal husbandry and considers the need for a specific status for these products

ANSES assesses the efficacy and safety of alternatives to antibiotics in animal husbandry and considers the need for a specific status for these products

Today, the Agency is publishing an inventory of alternatives to antibiotics aimed at reducing their use in animal husbandry and based on an original method for evaluating the diverse scientific publications in the field. In its report, ANSES identifies numerous products and substances including compounds, plants, plant extracts and micro-organisms, which are used as alternatives to antibiotics. However, it emphasises the diversity of the data available to assess their safety and efficacy, and their abili...

France - Agence Nationale du Médicament Vétérinaire

17-4-2018

March 27, 2018: Compounding Pharmacy Owner Sentenced to Five Years in Prison for $10.5 Million Health Care Fraud

March 27, 2018: Compounding Pharmacy Owner Sentenced to Five Years in Prison for $10.5 Million Health Care Fraud

March 27, 2018: Compounding Pharmacy Owner Sentenced to Five Years in Prison for $10.5 Million Health Care Fraud

FDA - U.S. Food and Drug Administration

8-9-2009

Decision on future reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium compounds)

Decision on future reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium compounds)

On 3 september 2009, the Danish Medicines Agency decided on the future reimbursement status of medicinal products in ATC group A06 (laxatives) and A02AA04 (magnesium compounds).

Danish Medicines Agency

17-9-2018

Volon® A Salbe antibiotikafrei

Rote - Liste

10-7-2018

Chlorhexamed FORTE alkoholfrei 0,2 %

Rote - Liste